Objective characterization of liposomal drug delivery platforms

Liposomal particles for drug delivery

Our analysis services include assessment of quality attributes recommended in regulatory guidelines for drug delivery nanoparticles such as particle size distribution, particle morphology (including shape and lamellar structure), loading efficiency of liposomes (often referred to as ratio of filled vs empty), physical state of the encapsulated drug substance and more.

Cryo-transmission electron microscopy (cryoTEM) combined with image analysis using proprietary Vironova Analyzing Software (VAS) enables reliable quantitative data.

Choose your analysis

Particle size distribution
Arrow 33.4 Created with Sketch.

Size distribution of liposomes detected with VAS

Morphology including circularity
Arrow 33.4 Created with Sketch.

Shape (circularity) distribution analysis of liposomes detected by VAS

Packaging efficiency (full/empty ratio)
Arrow 33.4 Created with Sketch.

VAS software allows objective determination of drug content of liposomes

The VAS software measures whether the liposomes contain the drug or not. The program then presents a bar chart. The output of VAS analysis is a report with quantitative data.

Liposomal lamellarity
Arrow 33.4 Created with Sketch.

VAS is employed to quantify lamillarity classes

Thickness of liposomal bilayer
Arrow 33.4 Created with Sketch.

High magnification cryoTEM of liposomes supports measurements of bilayer thickness

The graph shows the thickness distribution in nm.

These analyses are part of our standard service offering. Take a closer look at VAS if you have your own acquired TEM images to analyze.

Sample description (optional)

Analysis objective (optional)

Services

Study Proposal Form

Please fill out the following information with as much detail as you can, in order for us to provide you with an accurate quote as soon as possible.

* - Compulsory fields
What is the nature of the product
If relevant, where will the product be marketed
Should the study be performed in compliance with GLP
Should the study be performed in duplicate
Will a representative from your company be present during the testing
Process steps to be tested Model viruses Processing time Number of points for sampling If representative(s) will be present, please specify for which step(s)
Vironova Biosafety
Thank you for your interest.